Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Article

Press Release

March 11, 2025

Insights into the Latest Trends in Pancreatic Cancer

Author(s):

Pancreatic Cancer Action Network

Key Takeaways

  • NCCN guidelines on genetic testing for hereditary cancers assist patients in understanding genetic risks and testing options, promoting informed healthcare decisions.
  • PanCAN's Early Detection Initiative explores the connection between new-onset diabetes and pancreatic cancer to develop early screening methods for high-risk individuals.
  • Disparities in pancreatic cancer incidence and mortality among Black Americans are linked to structural racism and healthcare access, necessitating advocacy and research funding.
  • PanCAN leaders advocate for federal investment in pancreatic cancer research to ensure sustained funding for scientific progress and improved patient outcomes.
SHOW MORE

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support.

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support. © - stock.adobe.com

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support. © - stock.adobe.com

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support. The National Comprehensive Cancer Network (NCCN) has released new patient-facing guidelines on genetic testing for hereditary cancers, including pancreatic cancer. These guidelines provide essential information on genetic risks, testing options, and early detection strategies, helping patients and their families make informed healthcare decisions. PanCAN strongly encourages genetic and tumor biomarker testing for all pancreatic cancer patients to guide personalized treatment and identify potential risks for family members.

PanCAN’s Early Detection Initiative (EDI) has successfully enrolled over 8,800 participants to study the link between new-onset diabetes and pancreatic cancer. The goal of this initiative is to develop a screening method for high-risk individuals that detects pancreatic cancer early when it is still surgically treatable. As data from the study continues to be analyzed over the coming years, researchers are hopeful that this initiative will lead to the implementation of a new screening strategy that improves early detection and patient outcomes.

Additionally, pancreatic cancer disproportionately affects Black Americans, who have higher incidence and mortality rates than other racial and ethnic groups. The American Cancer Society’s latest report attributes these disparities to structural racism and inequitable access to healthcare. Addressing these disparities requires continued advocacy and research funding. PanCAN leaders recently visited Capitol Hill to urge federal investment in pancreatic cancer research, emphasizing the importance of sustained funding for scientific progress and improved patient outcomes. PanCAN encourages supporters to engage in advocacy efforts to ensure that funding for life-saving research remains a national priority.

Read more from PanCAN’s Chief Scientific & Medical Officer Dr. Anna Berkenblit: https://pancan.org/news/research-spotlight-2/.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Speaking Out
Speaking Out
Speaking Out
Related Content
Advertisement
The Leukemia & Lymphoma Society, a nonprofit in funding blood cancer research, patient support and advocacy, is becoming Blood Cancer United on August 28: © stock.adobe.com.
August 15th 2025

The Leukemia & Lymphoma Society Unveils Name Change to Reach All Blood Cancer Patients

The Leukemia & Lymphoma Society
Site Logo
August 15th 2025

Katie Couric: Advice to My Younger Self

Katie Kosko Kristie L. Kahl
Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic PDAC: © stock.adobe.com.
August 15th 2025

Daraxonrasib Gains FDA Status for Certain Metastatic Pancreatic Cancer

Ryan Scott
Image of Tripp
August 15th 2025

Spotlighting Pancreatic Cancer Disparities in Black Communities

Ryan Scott
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer: © stock.adobe.com.
August 15th 2025

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

Spencer Feldman
William Ramshaw resides in the expansive Pacific Northwest. He is a six-year survivor of pancreatic cancer. Catch up on William’s blogs here!
August 15th 2025

Pancreatic Cancer Tried to Crash My Three Daughters’ Weddings

William Ramshaw
Related Content
Advertisement
The Leukemia & Lymphoma Society, a nonprofit in funding blood cancer research, patient support and advocacy, is becoming Blood Cancer United on August 28: © stock.adobe.com.
August 15th 2025

The Leukemia & Lymphoma Society Unveils Name Change to Reach All Blood Cancer Patients

The Leukemia & Lymphoma Society
Site Logo
August 15th 2025

Katie Couric: Advice to My Younger Self

Katie Kosko Kristie L. Kahl
Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic PDAC: © stock.adobe.com.
August 15th 2025

Daraxonrasib Gains FDA Status for Certain Metastatic Pancreatic Cancer

Ryan Scott
Image of Tripp
August 15th 2025

Spotlighting Pancreatic Cancer Disparities in Black Communities

Ryan Scott
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer: © stock.adobe.com.
August 15th 2025

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

Spencer Feldman
William Ramshaw resides in the expansive Pacific Northwest. He is a six-year survivor of pancreatic cancer. Catch up on William’s blogs here!
August 15th 2025

Pancreatic Cancer Tried to Crash My Three Daughters’ Weddings

William Ramshaw
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.